Phase Ib/II Trial of Interleukin-2 and PD-1 Checkpoint Inhibitor, Nivolumab In Metastatic Clear Cell Renal Cell Cancer
Phase of Trial: Phase I/II
Latest Information Update: 12 Sep 2017
At a glance
- Drugs Interleukin-2 (Primary) ; Nivolumab (Primary)
- Indications Carcinoma; Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- 12 Sep 2017 Trial design of the study presented at the 42nd European Society for Medical Oncology Congress.
- 22 Feb 2017 Status changed from not yet recruiting to recruiting.
- 14 Dec 2016 New trial record